Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Probable Alzheimer's Disease
NCT03856359Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in Alzheimer's disease (AD), sponsored by Duke University. Started Apr 2019; status: completed.
02
Drugs
rifaximin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03856359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856359.